These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Effects on food intake and blood lipids of cannabinoid receptor 1 antagonist treatment in lean rats. Bennetzen MF; Nielsen MP; Richelsen B; Pedersen SB Obesity (Silver Spring); 2008 Nov; 16(11):2451-5. PubMed ID: 18719671 [TBL] [Abstract][Full Text] [Related]
11. Effect of rimonabant, the cannabinoid CB1 receptor antagonist, on peripheral nerve in streptozotocin-induced diabetic rat. Liu WJ; Jin HY; Park JH; Baek HS; Park TS Eur J Pharmacol; 2010 Jul; 637(1-3):70-6. PubMed ID: 20406631 [TBL] [Abstract][Full Text] [Related]
12. Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity? Doggrell SA Expert Opin Pharmacother; 2005 Oct; 6(12):2141-4. PubMed ID: 16197364 [No Abstract] [Full Text] [Related]
13. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Poirier B; Bidouard JP; Cadrouvele C; Marniquet X; Staels B; O'Connor SE; Janiak P; Herbert JM Diabetes Obes Metab; 2005 Jan; 7(1):65-72. PubMed ID: 15642077 [TBL] [Abstract][Full Text] [Related]
14. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Thornton-Jones ZD; Kennett GA; Benwell KR; Revell DF; Misra A; Sellwood DM; Vickers SP; Clifton PG Pharmacol Biochem Behav; 2006 Jun; 84(2):353-9. PubMed ID: 16814374 [TBL] [Abstract][Full Text] [Related]
15. Haloperidol inhibits the development of atherosclerotic lesions in LDL receptor knockout mice. van der Sluis RJ; Nahon JE; Reuwer AQ; Van Eck M; Hoekstra M Br J Pharmacol; 2015 May; 172(9):2397-405. PubMed ID: 25572138 [TBL] [Abstract][Full Text] [Related]
16. Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior. Duarte C; Alonso R; Bichet N; Cohen C; Soubrié P; Thiébot MH Neuropsychopharmacology; 2004 May; 29(5):911-20. PubMed ID: 14694354 [TBL] [Abstract][Full Text] [Related]
17. Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition. Wilck N; Fechner M; Dreger H; Hewing B; Arias A; Meiners S; Baumann G; Stangl V; Stangl K; Ludwig A Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1418-26. PubMed ID: 22516063 [TBL] [Abstract][Full Text] [Related]
18. The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction. Lim SY; Davidson SM; Yellon DM; Smith CC Basic Res Cardiol; 2009 Nov; 104(6):781-92. PubMed ID: 19462153 [TBL] [Abstract][Full Text] [Related]
19. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Janiak P; Poirier B; Bidouard JP; Cadrouvele C; Pierre F; Gouraud L; Barbosa I; Dedio J; Maffrand JP; Le Fur G; O'Connor S; Herbert JM Kidney Int; 2007 Dec; 72(11):1345-57. PubMed ID: 17882151 [TBL] [Abstract][Full Text] [Related]
20. Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice. Hasan ST; Zingg JM; Kwan P; Noble T; Smith D; Meydani M Atherosclerosis; 2014 Jan; 232(1):40-51. PubMed ID: 24401215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]